KACI DEVILLIER: Open Payments
NPI 1477165132 · OPELOUSAS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$541 in 25 payments from 11 companies in 2025. Trend: 2023 $450 · 2024 $202 · 2025 $541
Food & beverage: $541
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $245 |
| ABBVIE INC. | 4 | $83 |
| Vanda Pharmaceuticals Inc. | 2 | $38 |
| Braeburn Inc. | 2 | $38 |
| Janssen Pharmaceuticals, Inc | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| E.R. Squibb & Sons, L.L.C. | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Lundbeck LLC | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
Products named: CAPLYTA, VRAYLAR, BRIXADI, SPRAVATO, Auvelity, COBENFY, UZEDY, HETLIOZ.
Industry payments across LA — which companies pay providers there.
